Snapshot from Jul 07, 2026 at 01:18 UTC. For live data and tracking: View Live
Entity

Paragon Therapeutics

Tracked across 2 events · 37 articles · First seen Jul 21, 2025 · Last active Jul 06, 2026

Sentiment
2
Attention
6
Events
2
Relationships
2
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 -70
Business
Impact: Paragon Therapeutics is facing a class action lawsuit for allegedly providing misleading statements regarding its lead cell therapy candidate drug, deramiocel, which led to a significant stock price decline after the United States — Food and Drug Administration denied its Biologics License Application.
Jul 21, 2025 · 31 articles
6 75
Regulatory
Impact: Paragon Therapeutics announced that the Cellular, Tissue, and Gene Therapies Advisory Committee of the United States — Food and Drug Administration will convene a meeting to discuss its Biologics License Application for Deramiocel, a cell therapy for Duchenne muscular dystrophy. This is a significant step towards potential market approval for their lead product candidate.
Jun 26, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Paragon Therapeutics live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.